MEDICAL NEWS SITES

Lungs-new-thumb-small.jpg

OncLive

NICE Recommends Against Frontline Osimertinib in EGFR-Mutant NSCLC


The United Kingdom’s National Institute for Health and Care Excellence (NICE) will not recommend osimertinib (Tagrisso) as a frontline treatment for patients with locally advanced or metastatic EGFR-mutant non–small cell lung cancer (NSCLC).


Read more

Sreeni_Chittoor_1.23.20-video-thumb.jpg

OncLive

Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLC


Sreeni Chittoor, MD, FACP, a medical oncologist and hematologist at Texas Oncology, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer (NSCLC). When performing molecular tests on patients with metastatic NSCLC, the focus is typically on EGFR, ROS1, ALK, BRAF, NTRK, RET, MET, AKT1, PTEN, and HER2 mutations, as these are druggable targets, explains Chittoor. Some mutations have more than 1 treatment available. For example, if a patient has an exon 19 deletion, patients can receive or gefitinib (Iressa), erlotinib (Tarceva), or osimertinib (Tagrisso) in the first-line setting.


Read more

Benjamin_Levy_1.23.20-video-thumb.jpg

OncLive

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer


Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers for immunotherapy in lung cancer. Levy anticipates, in the future, a combination of biomarkers will serve as an indication for patients to receive immunotherapy in lung cancer. Research is currently looking into markers within plasma, such as tumor mutational burden. Currently, PD-L1 is used to help guide decisions with immunotherapy. In addition to positive predictors of response, negative predictors must also be identified in lung cancer, says Levy.


Read more

BioSpace

Health Canada Approves KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)


KIRKLAND, QC, Jan. 23, 2020 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Inlyta® (axitinib), a tyrosine kinase inhibitor, for first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the pivotal Phase 3 KEYNOTE-426 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for KEYTRUDA® in combination with axitinib (KEYTRUDA®-axitinib combination) compared to sunitinib. For Canadians living with advanced renal cell carcinoma, the cancer has spre...


Read more

Onc_NETs_Ins_dec19_seg_06.jpg

OncLive

Somatostatin Analogue Trials and Indications


Browse by Series: New Indications for AR-Targeted Therapy on Prostate Cancer: Including ESMO 2019 Highlights The Future of RET Inhibitors in Non-Small Cell Lung and Thyroid Cancer AFP as a Prognostic and Predictive Marker in HCC ADT and the Risk of Major Adverse Cardiovascular Events Expert Perspective on the Treatment of Multiple Myeloma Novel Therapeutic Agents for Acute Myeloid and Chronic Lymphocytic Leukemia Best Practices for Utilizing Bone Targeted Therapy for Metastatic Prostate Cancer Community Focus: Expanding Use of CAR-T Therapy in Lymphoma Advances in the Treatment of Relapsed/Refractory Myeloma Evolution of The Continuum of Care for Metastatic CRC Antiangiogenic Therapy in the Current Landscape of NSCLC Balancing Efficacy and ...


Read more

84507.jpg

MedPageToday

Robotic Bronchoscopy Safe, Effective in Post-Marketing Study


Robotic bronchoscopy was found to have a low complication rate, with navigation success of 88.6% and an initial diagnostic yield of 69.1% to 77% among patients with lung lesions in the first multicenter, post-marketing study of the technology. The FDA cleared Auris Health's Monarch robotic endoscopy platform in the spring of 2018 for diagnostic and therapeutic bronchoscopic procedures. The new retrospective analysis, published online in BMC Pulmonary Medicine by a team led by Udit Chaddha, MD, of Icahn School of Medicine at Mount Sinai in New York City, and Stephen Kovacs, DO, of UPMC Hamot in Pittsburgh, included 165 patients with lung lesions who underwent robot-assisted bronchoscopy at four treatment centers from mid-June to mid-Decemb...


Read more

84497.jpg

MedPageToday

HPV Vax Efficacy Questioned; Bio$imilar Market Effect$; 'Lighting Up' Cells May Cut Toxicity


An analysis of a dozen published studies of human papillomavirus vaccines raised questions about the vaccines' ability to prevent cervical cancer. (Journal of the Royal Society of Medicine) Biosimilar drugs will have a major impact on U.S. drug costs in 2020, building on the 2019 launch of two oncology biosimilars, Mvasi (bevacizumab, Avastin) and Kanjinti (trastuzumab, Herceptin). (GlobalData) A preliminary test of a new type of breast imaging based on principles of magnetics showed potential for distinguishing between active and inactive regions of breast tumors.


Read more

ASH19_CART_PX_Seg03.jpg

OncLive

Treating Common Toxicities From CAR T Therapy


Browse by Series: All Peer Exchange Advanced Breast Cancer A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia The Evolving Role of CAR T Cell Therapy in Hematological Malignancies Extensive Stage Small-Cell Lung Cancer Prostate Cancer: Evolving Treatment Approaches Advanced Ovarian Cancer: New Perspectives on Systemic Therapy Multimodality Management of Advanced Liver Cancer Precision Medicine: A New Frontier for Advanced Cholangiocarcinoma Non-Small-Cell Lung Cancer: Perspectives on Key Data Advances in the Treatment of Prostate Cancer Recent Developments in Management of Gynecologic Cancers Contemporary Management of Metastatic Renal Cell Carcinoma Updates in the Management of Follicular Lymphoma Updates in Targeted Therapies for...


Read more

ASH19_CART_PX_Seg02.jpg

OncLive

A Conversation on MRD in ALL


Browse by Series: All Peer Exchange Advanced Breast Cancer A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia The Evolving Role of CAR T Cell Therapy in Hematological Malignancies Extensive Stage Small-Cell Lung Cancer Prostate Cancer: Evolving Treatment Approaches Advanced Ovarian Cancer: New Perspectives on Systemic Therapy Multimodality Management of Advanced Liver Cancer Precision Medicine: A New Frontier for Advanced Cholangiocarcinoma Non-Small-Cell Lung Cancer: Perspectives on Key Data Advances in the Treatment of Prostate Cancer Recent Developments in Management of Gynecologic Cancers Contemporary Management of Metastatic Renal Cell Carcinoma Updates in the Management of Follicular Lymphoma Updates in Targeted Therapies for...


Read more

;w=625;h=350

BioSpace

NovoCure Positions Itself for Nearing Clinical Readouts


Bill Doyle, executive chairman of the board of directors for NovoCure, said 2019, which included the U.S. approval of the first treatment for mesothelioma in 15 years, was an incredible year “on all fronts” for the company. That was the message Doyle and other NovoCure executives delivered in San Francisco at the annual J.P. Morgan Healthcare Conference. Doyle spoke to BioSpace following the conclusion of the conference where he touted the achievements the company has made with its Tumor Treating Fields platform in solid tumors.


Read more

Onc_NETs_Ins_dec19_seg_07.jpg

OncLive

Somatostatin Analogue Dosing Strategies


Browse by Series: New Indications for AR-Targeted Therapy on Prostate Cancer: Including ESMO 2019 Highlights The Future of RET Inhibitors in Non-Small Cell Lung and Thyroid Cancer AFP as a Prognostic and Predictive Marker in HCC ADT and the Risk of Major Adverse Cardiovascular Events Expert Perspective on the Treatment of Multiple Myeloma Novel Therapeutic Agents for Acute Myeloid and Chronic Lymphocytic Leukemia Best Practices for Utilizing Bone Targeted Therapy for Metastatic Prostate Cancer Community Focus: Expanding Use of CAR-T Therapy in Lymphoma Advances in the Treatment of Relapsed/Refractory Myeloma Evolution of The Continuum of Care for Metastatic CRC Antiangiogenic Therapy in the Current Landscape of NSCLC Balancing Efficacy and ...


Read more

ASH19_CART_PX_Seg04.jpg

OncLive

CAR T-Cell Therapy: Relapsed/Refractory ALL


Browse by Series: All Peer Exchange Advanced Breast Cancer A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia The Evolving Role of CAR T Cell Therapy in Hematological Malignancies Extensive Stage Small-Cell Lung Cancer Prostate Cancer: Evolving Treatment Approaches Advanced Ovarian Cancer: New Perspectives on Systemic Therapy Multimodality Management of Advanced Liver Cancer Precision Medicine: A New Frontier for Advanced Cholangiocarcinoma Non-Small-Cell Lung Cancer: Perspectives on Key Data Advances in the Treatment of Prostate Cancer Recent Developments in Management of Gynecologic Cancers Contemporary Management of Metastatic Renal Cell Carcinoma Updates in the Management of Follicular Lymphoma Updates in Targeted Therapies for...


Read more

;w=625;h=350

BioSpace

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market


Earlier this week, BeiGene, with offices in Beijing, China and Cambridge, Massachusetts, announced results from its pivotal Phase III trial of its anti-PD-1 antibody tislelizumab in combination with two chemotherapy agents in squamous non-small cell lung cancer (NSCLC). The drug, a checkpoint inhibitor, met the primary endpoint of improved progression-free survival (PFS) at the planned interim analysis. If tislelizumab is approved, it sets the company on a collision course with the dominant player in the checkpoint inhibitor market, Merck and it’s Keytruda (pembrolizumab). Beigene indicated it plans to seek approval in China.


Read more

Indivumed_Logo.jpg

BioSpace

Evotec and Indivumed Announce Second Joint Drug Discovery Program


Partnership Aims to Replicate Successful Milestone Achievement from Revolutionary Joint Drug Discovery Program in Colorectal Cancer HAMBURG, Germany, Jan. 23, 2020 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH ("Indivumed") today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer ("NSCLC"). The final goal of this precision medicine collaboration is to deliver highly effective treatments for NSCLC patients. The collaboration will combine Evotec's proprietary bioinformatics analysis platform "PanHunter," as well as its small molecule and antibody disc...


Read more

BioSpace

Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market


AUSTIN, Texas CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.


Read more

BioSpace

BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors


NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointments of Drs. Daniel Zabrowski and Ramon Mohanlal to the Company’s Board of Directors. Dr. Zabrowski previously worked for more than 20 years at Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations and Global Head of Pharma Partnering.


Read more

dt_200122_kidney_cancer_800x450.jpg

MedScape

Fat Near Kidney Tumors May Explain 'Obesity Paradox'


Body fat near kidney tumors may be instrumental in how well cancer treatment works and the related survival of a patient, according to the authors of a new cohort study of patients with renal cell carcinoma (RCC). In obese individuals, "perinephric" fat is denser and significantly more inflamed, which in turn may trigger an advantageous immune response, report lead author Alejandro Sanchez, MD, Huntsman Cancer Institute, University of Utah in Salt Lake City, and colleagues. The findings lend support to — and may offer insight into — the "obesity paradox" in RCC, whereby overweight individuals are at higher risk for the disease but have better cancer outcomes compared with individuals of normal weight. Notably, obese patients did not harb...


Read more

JOURNALS

favicon.ico

Dove Press

ZNF671 Inhibits the Proliferation and Metastasis of NSCLC via the Wnt/ | CMAR


Wei Zhan, 1 Yuzhe Li, 2 Xuhui Liu, 1 Changlong Zheng, 1 Yongmei Fu 1 1Department of Emergency, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, People’s Republic of China; 2Department of Clinical Laboratory, The Third Affiliated Hospital of Sun Yat-Sen University, Lingnan Hospital, Guangzhou 510080, People’s Republic of China Correspondence: Yongmei Fu Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, People’s Republic of China Email Zheng The Third Hospital of Sun Yat-Sen University, Guangzhou 510630, China Email Lung cancer is the most common cancer in the world and is the main cause of cancer-related death.


Read more

259.jpg

Springer

Influx rate constant of 18 F-FDG increases in metastatic lymph nodes of non-small cell lung cancer patients


Primary tumor (PT) and metastatic lymph node (MLN) status have a great influence on diagnosis and treatment of lung cancer. Our main purpose was to investigate the imaging characteristics of PT or MLN by applying the 18F-FDG PET dynamic modeling approach for non-small cell lung cancer (NSCLC). Dynamic 18F-FDG PET scans were performed for 76 lung cancer patients, and 62 NSCLC cases were finally included in this study: 37 with newly diagnosed early and locally advanced lung cancer without distant metastases (group M0) and 25 metastatic lung cancer (group M1).


Read more

41598_2020_58010_Fig1_HTML.png

Nature

The optimal sequence of bronchial brushing and washing for diagnosing peripheral lung cancer using non-guided flexible bronchoscopy


In this study, the overall diagnostic yield of performing washing after brushing in patients with peripheral lung cancer during non-guided FB was 52.4%, and washing had a significantly higher diagnostic yield than that of brushing. Furthermore, 15.1% of all cases had positive washing, but negative brushing, results. These results provide evidence for the optimal sequence of bronchial brushing and washing for the diagnosis of peripheral lung cancer during non-guided FB. The global sensitivities of brushing and washing for the diagnosis of peripheral lung cancer are 54% (range 16–84%) and 43% (range 12–65%), respectively3.


Read more

favicon.ico

Dove Press

pH- and Ultrasound-Responsive Paclitaxel-Loaded Carboxymethyl Chitosan | IJN


Chemoradiotherapy (CRT), which refers to the synergistic administration of chemotherapy and radiotherapy (RT), now plays an important role in cancer oncology.1,2 The main rationale of CRT is provoked to be an increasing therapeutic effect of RT by drug-induced sensitization of tumor tissue.2 Significant evidence has existed supporting the use of CRT as a primary effective curative approach for many solid cancers, such as head and neck, esophageal, lung, pancreatic and prostate cancers.3–7 Even though CRT might be favored by many physicians, aggressive therapy is still associated with several obstacles, including the increases in side effects and systemic toxicity.8,9 Hence, much advancements are in urgent need to further improve the therape...


Read more

favicon.ico

Dove Press

LncRNA SNHG1 Regulates the Progression of Esophageal Squamous Cell Can


Esophageal cancer with the sixth cancer deaths consists of esophageal squamous cell cancer and esophageal adenocarcinoma, and esophageal squamous cell cancer predominates worldwide.1 Therefore, this study focuses on esophageal squamous cell cancer. Recently, great advances have been gained for the pathogenesis, diagnosis and treatment of esophageal squamous cell cancer.2 However, the survival of patients remains poor.3 Hence, much hope is placed in understanding the pathogenesis and exploring a novel strategy for the treatment of esophageal squamous cell cancer. Noncoding RNAs, including long noncoding RNAs (lncRNAs) with more than 200 nucleotides and microRNAs (miRNAs), have been reported to be aberrantly expressed and associated with can...


Read more

favicon.ico

Dove Press

Clinicopathological and Prognostic Significance of EML4-ALK Rearrangem | CMAR


Tyrosine kinase inhibitors (TKIs) are a class of pharmaceutical drugs that show beneficial effects in non-small cell lung cancer (NSCLC) patients harboring specific molecular alterations with less toxicity compared to chemotherapy and radiotherapy. They function as anticancer agents by targeting oncogene-driven signaling pathways and thus improving patients’ survival and quality of life.1,2 The investigations on TKIs contribute to the development of therapeutic interventions for NSCLC patients. The translocation and inversion of anaplastic lymphoma kinase (ALK) have been detected in a subset of NSCLC patients, especially the ones diagnosed with adenocarcinoma.


Read more

12967_2020_2218_Fig1_HTML.png

Springer

Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy


Abstract We have previously shown that HCC patients and healthy subjects are equally responsive to a RNAdjuvant®, a novel TLR-7/8/RIG-I agonist based on noncoding RNA developed by CureVac, by an ex vivo evaluation. However, the immunological effect of adjuvants on immune cells from cancer patients undergoing chemotherapy remains to be demonstrated. Different adjuvants currently used in cancer vaccine clinical trials were evaluated in the present study on immune cells from cancer patients before and after chemotherapy in an ex vivo setting. PBMCs were obtained from 4 healthy volunteers and 23 patients affected by either colon (OMA) or lung cancer (OT).


Read more

Nature

Cancer immunotherapy - Latest research and news | Nature


The CHECKMATE-227 trial of nivolumab and ipilimumab presents a potential new frontline chemotherapy-sparing treatment option for patients with PD-L1-positive non-small-cell lung cancer and perhaps, in the future, also for those with PD-L1-negative disease. Indeed, the true predictive value of PD-L1 as well as tumour mutational burden remains to be determined, as neither biomarker segregates clearly with responsiveness.


Read more

FINANCE SITES

isolated_1188036_960_720.png

Seeking Alpha

OncoCyte Enters Into The Cancer Immunotherapy Field With The Acquisition Of Insight Genetics


As in my previous articles, I can say that OCX offers a very interesting long-term investment with an impressive bullish potential. OncoCyte surprises us again with an acquisition, this time it has been Insight Genetics (IG). OncoCyte (NASDAQ:OCX) surprises us again with an acquisition, this time it has been Insight Genetics (IG). On 01/10/20 OCX reported that it had reached an agreement with IG for the acquisition of the total IG shares for an amount of $12M, $7M in cash plus $5M in OCX shares. This acquisition enables OCX to enter into the oncological immunotherapy field.


Read more

79e8dda789b9d47e8d6751b08af56fb9

Yahoo Finance

US Navy Veterans Mesothelioma Has Endorsed the Law Firm of Karst von Oiste and Attorney Erik Karst Now Offers to Prevent a Navy Veteran with Mesothelioma from Being Shortchanged on Compensation-Nationwide


NEW YORK, Jan. 23, 2020 /PRNewswire/ -- The US Navy Veterans Mesothelioma Advocate is urging a US Navy Veteran with mesothelioma in any state or their family to call them anytime at 800-714-0303 for direct access to attorney Erik Karst of the KVO-Karst von Oiste law firm. The Advocate does not want a Navy Veteran with this rare cancer caused by asbestos exposure or their family members playing financial compensation roulette with law firms offering 'free' books, packages, kits or calculators. They also fear that local car accident attorneys suggesting they have experience with mesothelioma compensation claims could result in a Navy Veteran getting shortchanged. Attorney Erik Karst and his colleagues at the law firm of Karst von Oiste are r...


Read more

yahoo_default_logo.png

Yahoo Finance

Delaware, CRISPR and Cellicon Valley: A Special Event on February 6th


DelawareBio, a nonprofit trade organization with the mission of catalyzing growth in the state's life-science industry, presents a panel discussion on gene editing that goes beyond CRISPR technology. To be held Thursday, February 6th from 1:30-5pm at the ChristianaCare John H. Ammon Medical Education Center, the event will provide an overview of the opportunities and challenges expected in bringing genome editing from the laboratory to the patient bedside. WILMINGTON, Del., Jan. 23, 2020 /PRNewswire-PRWeb/ -- DelawareBio, a nonprofit trade organization with the mission of catalyzing growth in the state's life-science industry, presents a panel discussion on gene editing that goes beyond CRISPR technology.


Read more

06c03b9b3d46d60d3a2a80f73822382f

Yahoo Finance

Researchers at Rush University Medical Center Find That Injecting Influenza Vaccines Into Tumors Triggers Immune System Response


CHICAGO, Jan. 23, 2020 /PRNewswire/ -- Changing the microenvironment of tumors to increase the immune system's response to them has been the goal of countless research and clinical studies including the most recent use of checkpoint inhibitory antibodies. The majority of patients have tumors that are "cold" -- that is, the tumors don't contain many immune cells, or they have cells that suppress the ability of the immune system to fight them. Increasing immune cells within a tumor can change it from "cold" to "hot" -- more recognizable to the immune system.


Read more

ti?nf=Nzc5NDQ5MCMzMzAxNDA4IzIxODgyNTg=

Yahoo Finance

The airway stent/lung stent market is projected to reach USD 120 million by 2024 from USD 87 million in 2019, at a CAGR of 6.7%


The. Factors such as rise in prevalence of lung cancer, increasing incidence of chronic respiratory diseases, continuous growth in the healthcare industry, and rising preference towards minimally invasive procedures are expected to drive the growth of the airway stent/lung stent market. New York, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Airway Stent/Lung Stent Market by Type, End User - Global Forecast to 2024" - However, the complications associated with stents and the availability of alternative treatments are anticipated to impede the growth of this market to a certain extent. The tracheobronchial stents segment is projected to witness the highest growth during the forecast period. ...


Read more

ti?nf=Nzc5NDI2NCMzMzAwNjcwIzIwODA4ODQ=

Yahoo Finance

BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors


NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointments of Drs. Daniel Zabrowski and Ramon Mohanlal to the Company’s Board of Directors. Dr. Zabrowski previously worked for more than 20 years at Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations and Global Head of Pharma Partnering.


Read more

yahoo_default_logo.png

Yahoo Finance

Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market


Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.


Read more

SOCIAL MEDIA

ProfilePicture.png

Twitter

OncLive.com NSCLC, lcsm, lcam: 23/01/2020 17:18:51


NICE Recommends Against Frontline Osimertinib in EGFR-Mutant #NSCLC #lcsm #lcam


Read more

ProfilePicture.png

Twitter

OncLive.com NSCLC, lcsm, lcam: 24/01/2020 02:10:04


The United Kingdom’s National Institute for Health and Care Excellence will not recommend osimertinib as a frontline treatment for patients with locally advanced or metastatic EGFR-mutant #NSCLC #lcsm #lcam


Read more

ProfilePicture.png

Twitter

Paperbirds_Oncology lungcancer, oncology: 23/01/2020 12:45:33


New clinical trial: Clinical Trial Assessing the Effecacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC


Read more

ProfilePicture.png

Twitter

Targeted Oncology lungcancer: 23/01/2020 15:01:30


Dr. Besse explained the use of genomic testing to aid the treatment of non-small cell lung cancer.


Read more

ProfilePicture.png

Twitter

Genprex, Inc. : 23/01/2020 15:59:42


FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC


Read more

ProfilePicture.png

Twitter

Renal Cell Carcinoma : 23/01/2020 18:20:01


NICE Recommends Against Frontline Osimertinib in EGFRMutant NSCLC: The United Kingdom’s National Institute for Health and Care Excellence will not recommend osimertinib as a frontline treatment for patients with locally advanced or metastatic…


Read more

ProfilePicture.png

Twitter

Tal Varsano : 23/01/2020 23:17:58


ImmunoSCAPE's joint publication with Genentech in the Journal for ImmunoTherapy of Cancer, Oct 2019. Mass cytometry (CyTOF®), together with cellular ‘barcoding’ utilized to profile immune cells from non-small cell lung cancer (NSCLC) patients during anti…


Read more

ProfilePicture.png

Twitter

Dr. Saadvik Raghuram y : 24/01/2020 02:23:04


NICE Recommends Against Frontline Osimertinib in EGFR-Mutant NSCLC


Read more